Virtus LifeSci Biotech Clinical Trials ETF
19 hedge funds and large institutions have $11.4M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$84.2K | |
| 2 | +$67.6K | |
| 3 | +$60.2K | |
| 4 |
Morgan Stanley
New York
|
+$27.1K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$8K |
Top Sellers
| 1 | -$603K | |
| 2 | -$571K | |
| 3 | -$377K | |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$108K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$54K |